Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

G Protein-coupled Estrogen Receptor Antibodies

Close filters
No results were found for the filter!
Rabbit Monoclonal
NEW
GPER/GPR30 [UMB27] (RM-non-phospho-G Protein-Coupled Estrogen Receptor Antibody), Rabbit Monoclonal
GPER/GPR30 [UMB27] (RM-non-phospho-G...
The non-phospho-GPER/GPR30 antibody is directed against the distal end of the carboxyl-terminal tail of human GPER/GPR30. It can be used to detect total GPER/GPR30 receptors in Western blots independent of phosphorylation. The GPER/GPR30...
$ 495.00 *
Rabbit Monoclonal
NEW
GPER/GPR30 [UMB27] (RM-IHC-Grade-G Protein-Coupled Estrogen Receptor Antibody), Rabbit Monoclonal
GPER/GPR30 [UMB27] (RM-IHC-Grade-G...
The non-phospho-GPER/GPR30 antibody is directed against the distal end of the carboxyl-terminal tail of human GPER/GPR30. It can be used to detect total GPER/GPR30 receptors in Western blots independent of phosphorylation. The GPER/GPR30...
$ 495.00 *

The G protein-coupled estrogen receptor (GPER, formerly GPR30) is a seven-transmembrane receptor that mediates rapid responses to estrogens. Its principal endogenous agonist is 17β-estradiol. The synthetic agonist G-1 and the antagonists G15 and G36 are widely used to distinguish GPER-mediated responses from those mediated by the classical estrogen receptors ERα and ERβ. Tamoxifen and fulvestrant can also activate GPER in some experimental systems. Depending on the cell type, GPER activation can alter intracellular cAMP and calcium levels and transactivate the epidermal growth factor receptor, leading to ERK and PI3K–AKT signaling. GPER expression has been reported in reproductive tissues, the cardiovascular system, the central nervous system, and several immune cell populations. GPER has been detected at the plasma membrane, although in many cell types it is found predominantly in intracellular compartments, including the endoplasmic reticulum. Cell-surface GPER can undergo constitutive, ligand-independent internalization and subsequent proteasomal degradation via a pathway that involves the trans-Golgi network. GPER expression is also regulated at the transcriptional level, with hormonal signals and growth factors influencing receptor abundance in a cell type-dependent manner. The oral selective GPER agonist LNS8801 has entered clinical testing as monotherapy and in combination with pembrolizumab for advanced cancers, including refractory melanoma, and no selective GPER-targeted drug is currently approved for clinical use. For more information on GPER receptor pharmacology please refer to the IUPHAR database.

The G protein-coupled estrogen receptor (GPER, formerly GPR30) is a seven-transmembrane receptor that mediates rapid responses to estrogens. Its principal endogenous agonist is 17β-estradiol. The... read more »
Close window
G Protein-coupled Estrogen Receptor Antibodies

The G protein-coupled estrogen receptor (GPER, formerly GPR30) is a seven-transmembrane receptor that mediates rapid responses to estrogens. Its principal endogenous agonist is 17β-estradiol. The synthetic agonist G-1 and the antagonists G15 and G36 are widely used to distinguish GPER-mediated responses from those mediated by the classical estrogen receptors ERα and ERβ. Tamoxifen and fulvestrant can also activate GPER in some experimental systems. Depending on the cell type, GPER activation can alter intracellular cAMP and calcium levels and transactivate the epidermal growth factor receptor, leading to ERK and PI3K–AKT signaling. GPER expression has been reported in reproductive tissues, the cardiovascular system, the central nervous system, and several immune cell populations. GPER has been detected at the plasma membrane, although in many cell types it is found predominantly in intracellular compartments, including the endoplasmic reticulum. Cell-surface GPER can undergo constitutive, ligand-independent internalization and subsequent proteasomal degradation via a pathway that involves the trans-Golgi network. GPER expression is also regulated at the transcriptional level, with hormonal signals and growth factors influencing receptor abundance in a cell type-dependent manner. The oral selective GPER agonist LNS8801 has entered clinical testing as monotherapy and in combination with pembrolizumab for advanced cancers, including refractory melanoma, and no selective GPER-targeted drug is currently approved for clinical use. For more information on GPER receptor pharmacology please refer to the IUPHAR database.

Recently viewed